Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

Agios Reports First Quarter 2017 Financial Results

GlobeNewswire May 4, 2017

Agios Announces Closing of Over-Allotment Option in Public Offering

GlobeNewswire April 28, 2017

Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target

GlobeNewswire April 27, 2017

Agios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017

GlobeNewswire April 27, 2017

Agios Announces Exercise of Over-Allotment Option in Public Offering

GlobeNewswire April 26, 2017

Agios Announces Closing of Public Offering

GlobeNewswire April 24, 2017

Agios Announces Proposed Offering of Common Stock

GlobeNewswire April 17, 2017

Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017

GlobeNewswire March 30, 2017

Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene

GlobeNewswire March 13, 2017

How These Biotech Stocks are Faring? -- bluebird bio, Opexa Therapeutics, Agios Pharma, and PTC Therapeutics

PR Newswire March 8, 2017

FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation

Business Wire March 1, 2017

Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017

GlobeNewswire February 28, 2017

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017

GlobeNewswire February 9, 2017

Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch

Benzinga.com  January 17, 2017

Technical Reports on Biotech Stocks -- Halozyme Therapeutics, Keryx Biopharma, Curis, and Agios Pharma

PR Newswire January 12, 2017

Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017

GlobeNewswire January 9, 2017

Agios Appoints Ian Clark to Board of Directors

GlobeNewswire January 3, 2017

Agios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017

GlobeNewswire January 3, 2017

Why The Last Week Of 2016 Could Be Big For Biotech Catalysts

Benzinga.com  December 27, 2016

Agios Pharma Shares Crushed Under Weight Of Clinical Setback

Benzinga.com  December 16, 2016